Adipotide vs BPC-157
Emerging vs Extensively Studied
compatible No known direct interaction; distinct mechanisms and targets.
Molecular Data
Adipotide BPC-157
Weight N/A 1,419.53 Da
Half-life Not established <30 minutes
Chain N/A 15 amino acids
Type Chimeric peptidomimetic Pentadecapeptide
Key Benefits
Adipotide
01 Rapid fat-mass reduction via selective white adipose tissue vascular targeting
02 Improved insulin sensitivity following adipose reduction
03 Non-CNS peripheral mechanism distinct from appetite suppressants
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Dosing Protocols
Adipotide
0.43 mg/kg / Once daily
Primate Research Replication 0.43 mg/kg Once daily
Dose-Finding (Research) 0.10-0.75 mg/kg Once daily (escalating tiers)
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Side Effects
Adipotide
Mild creatinine elevation
Electrolyte shifts
Dose-dependent proximal tubule changes (reversible in primates)
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Contraindications
Pregnancy/lactation (not studied)
Dehydration
Concurrent nephrotoxic medications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Research Evidence
Adipotide BPC-157
Status Emerging Extensively Studied
References 4 studies 6 studies
Latest — January 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.